All In MedTech

FDA Clearance Tracker · P210002

therascreen PDGFRA RGQ PCR Kit

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jun 29, 2023 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 29, 2023

Approved

Time to decision

881 days

Received Jan 29, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P210002
Device name
therascreen PDGFRA RGQ PCR Kit
Applicant
QIAGEN GmbH
Applicant location
Hilden
Received
Jan 29, 2021
Decided
Jun 29, 2023
Decision
Approved

Device type

Device class
Class III

Every decision under product code OWD

FDA's approval statement

As written in FDA's record.

Approval for the therascreen PDGFRA RGQ PCR Kit. The QIAGEN therascreen® PDGFRA RGQ PCR Kit is a real-time qualitative in vitro diagnostic assay for the detection of the D842V somatic mutation in the PDGFRA gene using genomic DNA extracted from Gastrointestinal Stromal Tumor (GIST) patients formalin-fixed paraffin-embedded (FFPE) tumor tissue. The therascreen PDGFRA RGQ PCR Kit is intended for use as a companion diagnostic test, to aid clinicians in identification of patients with GIST who may be eligible for treatment with AYVAKIT (avapritinib) based on a PDGFRA mutation detected result. FFPE tumor specimens are processed using the QIAamp® DSP DNA FFPE Tissue Kit for manual sample preparation and the Rotor-Gene® Q (RGQ) MDx instrument for automated amplification and detection. The therascreen PDGFRA RGQ PCR Kit is to be used by trained personnel in a professional laboratory environment.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code OWD. The earliest in FDA's data is P110020, decided Aug 17, 2011.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for QIAGEN GmbH

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.